ROCKVILLE, Md., Dec. 1, 2017 /PRNewswire/ -- CASI
Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and
other unmet medical needs announces a poster presentation on ENMD-2076 at the 2017 San Antonio Breast Cancer
SymposiumTM (SABCS), December 5-9, 2017 in San Antonio,
Texas.
ENMD-2076 is currently in a Phase 2 trial for the treatment of triple-negative breast cancer (TNBC) at two locations in the
U.S. The poster will be presented in the session listed below and will be available on the CASI Pharmaceuticals website after the
conclusion of the presentation.
Program Number: PD3-16
Abstract Number: 272
Session Title: Novel Drugs / Predicting Response for HER2+ Breast Cancer
Session Date: Thursday, December 7, 2017
Session Time: 7:00:00 AM – 9:00:00 AM CST
Title: "Clinical Safety and Efficacy of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated, Locally
Advanced or Metastatic Triple-Negative Breast Cancer"
About CASI Pharmaceuticals, Inc.
CASI is a U.S. based, late-stage biopharmaceutical company focused on the acquisition, development and commercialization of
innovative therapeutics addressing cancer and other unmet medical needs for the global market with a focus on commercialization
in China. CASI's product pipeline features (1) EVOMELA®, MARQIBO® and
ZEVALIN®, all U.S. Food and Drug Administration (FDA) approved drugs in-licensed from Spectrum Pharmaceuticals, Inc.
for China regional rights, and currently in various stages in the regulatory and clinical
process for market approval in China, (2) CASI-001 and CASI-002, proprietary preclinical
candidates in immune-oncology, and (3) our proprietary drug candidate, ENMD-2076, ongoing in one Phase 2 clinical study. CASI is
headquartered in Rockville, Maryland and has a wholly owned subsidiary and R&D operations in
Beijing, China. More information on CASI is available at www.casipharmaceuticals.com and in CASI's filings with the U.S.
Securities and Exchange Commission.
CASI's China rights to EVOMELA® (melphalan) for Injection, MARQIBO®
(vinCRIStine sulfate LIPOSOME injection) and ZEVALIN® (ibritumomab tiuxetan) were previously licensed from its partner
Spectrum Pharmaceuticals, Inc. Based on the U.S. FDA's approval of these three licensed products, CASI is pursuing the Import
Drug registration path for approval in China.
Forward Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with
respect to the outlook for expectations for future financial or business performance, strategies, expectations and
goals. Forward looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.
Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.
Actual results could differ materially from those currently anticipated due to a number of factors, including: that we may be
unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the
volatility in the market price of our common stock; risks relating to interests of our largest stockholders that differ from our
other stockholders; the risk of substantial dilution of existing stockholders in future stock issuances, the difficulty of
executing our business strategy in China; our inability to predict when or if our product
candidates will be approved for marketing by the China Food and Drug Administration authorities; our inability to enter into
strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates
or future candidates; risks relating to the need for additional capital and the uncertainty of securing additional funding on
favorable terms; risks associated with our product candidates; risks associated with any early-stage products under development;
the risk that results in preclinical and early clinical models are not necessarily indicative of later clinical results;
uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of
success in the clinical development of any of our products; dependence on third parties; and risks relating to the
commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply,
competition and other risks). Such factors, among others, could have a material adverse effect upon our business, results of
operations and financial condition. We caution readers not to place undue reliance on any forward-looking statements, which only
speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition
and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, which are available at
www.sec.gov.
EVOMELA ®, MARQIBO ® and ZEVALIN ® are proprietary to Spectrum
Pharmaceuticals, Inc. and its affiliates.
View original content with multimedia:http://www.prnewswire.com/news-releases/casi-pharmaceuticals-announces-poster-presentation-at-the-2017-san-antonio-breast-cancer-symposiumtm-sabcs-on-enmd-2076-in-patients-with-triple-negative-breast-cancer-tnbc-300564581.html
SOURCE CASI Pharmaceuticals, Inc.